Vedanta Biosciences
04/02/2026: Vedanta Biosciences Announces the Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection Will Continue as Planned Following Protocol-Specified Interim Analysis Learn More Commitment to Patients Gut dysbiosis is a known driver of gastrointestinal diseases. Our drugs can stimulate a range of protective responses which hold potential for the treatment of these diseases.
Basic Information
- Category: Microbiome
- Founded: 2010
- Headquarters: Cambridge, MA
- Website: vedantabio.com
Documented Facts
- Phone: +1857-706-1427 (No linked source recorded for this statement.)
Evidence and Sources
- Vedanta Biosciences — Official Site (official)
- Vedanta Biosciences on linkedin (social)
Citation Guidance
Explore Microbiome profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Vedanta Biosciences.
- Canonical profile: https://brandsource.ai/brands/vedanta-biosciences
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/vedanta-biosciences/json-ld
- Citation profile API: https://brandsource.ai/api/brands/vedanta-biosciences/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (81/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2025-10-28T04:26:11.880Z
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
04/02/2026: Vedanta Biosciences Announces the Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection Will Continue as Planned Following Protocol-Specified Interim Analysis Learn More Commitment to Patients Gut dysbiosis is a known driver of gastrointestinal diseases. Our drugs can stimulate a range of protective responses which hold potential for the treatment of these diseases.
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 1 supporting source linked.
- 1 structured fact available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.